Cancer & Body Imaging

Researchers led by Dr. Bachir Taouli at the BioMedical Engineering and Imaging Institute (BMEII) use state of the art methodology and equipment for the diagnosis and prognostication of cancers and diseases of the liver, kidney, and the bowel. Their primary focus is to develop noninvasive imaging techniques for screening, diagnosis, characterization, and response in patients with cancer and other diseases. The team’s publications can be found here.



Bachir Taouli, MD, MHA

Bachir Taouli, MD, MHA, is a Professor of Radiology and Medicine. He is the Director of Body MRI & Cancer Imaging, Co-Director of Abdominal Imaging, and Vice-chair of Translational Research in the Department of Diagnostic, Molecular and Interventional Radiology at the BioMedical and Engineering Imaging Institute (BMEII). His research is focused on the application of advanced MRI sequences to diffuse liver disease/liver cancer and abdominal and pelvic malignancies, including prostate cancer.

Sara Lewis, MD

Sara Lewis, MD, is an Associate Professor in the Department of Diagnostic, Molecular and Interventional Radiology. Her work is focused on conducting imaging research centered on the use of advanced MRI methods in characterizing hepatobiliary neoplasms, solid organ transplant dysfunction, prostate cancer and evaluation of tumor response to therapy.

Octavia Bane, PhD

Octavia Bane, PhD, is an Assistant Professor of Radiology at the Icahn School of Medicine at Mount Sinai. She has been a member of the Biomedical Engineering and Molecular Imaging Institute (BMEII) since 2013, when she joined the Body/Cancer MRI lab as a Post-Doctoral Fellow. Her interests lie in the application of MRI and radiomics in characterization of liver and kidney disease.


Advancing non-invasive techniques to detect, characterize, and personalize treatment for liver diseases

Click for more information

MRI is a versatile technique, with no radiation exposure, and the possibility of performing multiparametric imaging. Our lab applies MRI techniques to the detection and personalized intervention in liver diseases, including chronic liver disease, and liver cancer (hepatocellular carcinoma, HCC). Our researchers leverage MRI to develop non-invasive methods of disease detection, tumor characterization, prediction of disease progression and treatment response, and personalized therapies for patients with liver disease.

Inflammatory Bowel Disease

Developing accurate MRI techniques to better diagnose and characterize inflammatory bowel diseases


Click for more information

MRI of the bowel plays a crucial role for the assessment of patients with Crohn’s disease in the small bowel. Multiparametric MR Enterography, including diffusion and perfusion-weighted MRI and dynamic MRI for the assessment of inflammation, may potentially allow for a more complete assessment of active disease.


Developing non-invasive methods to predict patient outcomes

Click for more information

Chronic kidney disease (CKD) and the development of renal neoplasms, such as renal cell carcinoma (RCC), pose major impacts to kidney function and patient outcomes. Current techniques to assess kidney health, including biopsy, are invasive. Dr. Octavia Bane and Dr. Sara Lewis’ research group is testing advanced non-invasive MRI techniques as an alternative for the assessment of renal function, assessment of neoplasms, and prediction of patient outcomes.


Leveraging the power of MRI to detect and monitor prostate cancer progression

Click for more information

Prostate cancer (PCa) is the most common non-cutaneous malignancy occurring in men, with an urgent clinical need to identify men who would benefit from aggressive management versus those who could be managed with less invasive approaches. MRI has revolutionized the diagnostic and risk stratification pathway for individuals with PCa. Our group is actively involved in a wide variety of projects examining advanced imaging acquisition and quantitative analysis methods for non-invasive tumor detection, characterization, and longitudinal disease monitoring.



Using computational pattern recognition and machine learning to precisely characterize disease

Click for more information

Radiomics emerged as a quantitative tool for finding meaningful patterns in large numbers of images. Our team is investigating its applications to clinical imaging for the characterization of complex masses and predictive factors.

Response Evaluation Criteria in
Solid Tumors (RECIST)

Providing the most cutting edge techniques to track and adjust cancer treatment

Click for more information

RECIST is a method developed for objective assessment of the way a cancer patient’s body responds to various treatments. This is a standard method employed in cancer studies to track tumor progression across time. The Imaging Core provides these services to clinical researchers to monitor their patients on therapies. To learn more, click here.


Latest Publications

Artificial intelligence–enabled rapid diagnosis of patients with COVID-19

Xueyan Mei, Hao-Chih Lee, […] Yang Yang
Nat Med (2020).

Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging

Max L. Senders, Anu E. Meerwaldt, ... Willem J. M. Mulder
Nat. Nanotechnol. 15, 398–405 (2020).

For recent COVID-19 updates and information, please click here